Exact Sciences, RedHill Biopharma & more — 3 GI company key notes

Here are three updates on GI companies from the past week:

Exact Sciences posted $102.9 million in second quarter 2018 revenue, missing investor predictions by $1.8 million, or 1.7 percent, causing its stock to fall 18.75 percent.

Exact Sciences is sponsoring Fight Colorectal Cancer and PGA Tour professional Tom Lehman to promote Fight CRC.

RedHill Biopharma's Crohn's disease drug, RHB-104, successfully met its primary and secondary endpoints, achieving remission at 26 weeks.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.